Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. Tsukamoto S, Kido A, Tanaka Y, Facchini G, Peta G, Rossi G, Mavrogenis AF. Current overview of treatment for metastatic bone disease. Curr Oncol. 2021;28(5):3347–72.
2. Willeumier JJ, van der Linden YM, van der Wal CWPG, Jutte PC, van der Velden JM, Smolle MA, van der Zwaal P, Koper P, Bakri L, de Pree I, et al. An easy-to-use prognostic model for survival estimation for patients with symptomatic long bone metastases. J Bone Jt Surg Am. 2018;100:196–204.
3. Fletcher CDM, Sundaram M, Rydholm A, Coindre JM, Singer S. Soft tissue tumours: Epidemiology, clinical features, histopathological typical and grading. In: Fletcher CDM, Bridge JA, Hogendoorn P, Mertens, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Iarc; 2002.
4. Nandra R, Hwang N, Matharu GS, Reddy K, Grimer R. One-year mortality in patients with bone and soft tissue sarcomas as an indicator of delay in presentation. Ann R Coll Surg Engl. 2015;97(6):425–33.
5. Kawashima H, Ariizumi T, Yamagishi T, Ogose A, Ikoma M, Hotta T, Endo N. Symptom burden and end-of-life palliative treatments during the last two weeks of life in patients with advanced musculoskeletal sarcoma. J Palliat Med. 2019;22(8):908–14.